Immix Biopharma Reports 89% Complete Response Rate In Interim Phase 2 Data For NXC-201 In AL Amyloidosis; Plans BLA Submission Mid-2027
Share
Why It Matters
Immix's new medicine helped almost 9 out of 10 patients with a rare disease. This strong early result shows the company is moving closer to getting approval.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.